1. Home
  2. Labeler Index
  3. Golden State Medical Supply, Inc.
  4. 51407-893
  5. Product Images: Topiramate

Product Images Topiramate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Topiramate NDC 51407-893 by Golden State Medical Supply, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

51407-893-60OL - Topiramate 15 mg - Rev. 0424.jpg - 51407 893 60OL Topiramate 15 mg Rev. 0424

51407-893-60OL - Topiramate 15 mg - Rev. 0424.jpg - 51407 893 60OL Topiramate 15 mg Rev. 0424

Each capsule contains topiramate, USP equivalent to 15 mg. The capsules are white to off-white in color and contain coated pellets. The medication should be dispensed in a tight container and protected from moisture. The capsules are marked as "15 mg" and "TWi T210". It is important to keep this medication out of the reach of children and store it at 20° - 25°C. Pharmacies should dispense the Medication Guide to each patient. For further details, refer to the Prescribing Information available at the provided link.*

51407-894-60OL - Topiramate 25 mg - Rev. 0424.jpg - 51407 894 60OL Topiramate 25 mg Rev. 0424

51407-894-60OL - Topiramate 25 mg - Rev. 0424.jpg - 51407 894 60OL Topiramate 25 mg Rev. 0424

This text describes Topiramate capsules, USP, with NDC 51407-894-60. Each capsule contains topiramate equivalent to 25 mg. The medication guide should be dispensed to each patient. The capsules are white to off-white and spherical-shaped. It is important to store the medication in a tight container, protect from moisture, and keep it out of reach of children. The capsules are marked as "25 mg" on the body and "TWi T211" on the cap. Refer to the accompanying Prescribing Information for dosage details. Store between 20°-25°C (68°-77°F) with excursions permitted to 15°-30°C (59°-86°F) as per USP guidelines. Marketed by GSMS, Incorporated based in Camarillo, CA, 93012, USA.*

figure1 - figure 1

figure1 - figure 1

This is a chart displaying cumulative rates for the time to the first seizure between two groups of participants - one group taking Topamax 50 mg/day (N=234) and the other group taking Topamax 400 mg/day (N=236). The graph indicates that the higher dosage of Topamax (400 mg/day) resulted in a significantly lower rate of seizures compared to the lower dosage group. The p-value for this difference is 0.0002, showing a statistically significant result. The x-axis represents time in days and the y-axis shows the cumulative rates for seizures.*

figure2 - figure 2

figure2 - figure 2

This text provides information about the change from baseline in the average monthly migraine period rate during a double-blind phase for different dosages of Topamax compared to a placebo. The data shows the numbers of subjects in each group for the study. Note the significance level indicated by "*" and "**".*

logo - logo 2

logo - logo 2

structure - structure

structure - structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.